Cart
sales@molnova.com
Desfesoterodine
CAS No. 207679-81-0
Desfesoterodine ( PNU-200577; (R)-5-Hydroxymethyl Tolterodine )
Catalog No. M17424 CAS No. 207679-81-0
5-hydroxymethyl tolterodine (PNU 200577) is a new muscarinic receptor antagonist with Kb of 0.84 nM.
Purity : 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 132 | In Stock |
|
| 10MG | 205 | In Stock |
|
| 25MG | 353 | In Stock |
|
| 50MG | 520 | In Stock |
|
| 100MG | 750 | In Stock |
|
| 500MG | 1521 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDesfesoterodine
-
NoteResearch use only, not for human use.
-
Brief Description5-hydroxymethyl tolterodine (PNU 200577) is a new muscarinic receptor antagonist with Kb of 0.84 nM.
-
Description5-hydroxymethyl tolterodine (PNU 200577) is a new muscarinic receptor antagonist with Kb of 0.84 nM.
-
SynonymsPNU-200577; (R)-5-Hydroxymethyl Tolterodine
-
PathwayMetabolic Enzyme/Protease
-
TargetPhosphatase
-
RecptormAChR
-
Research AreaNeurological Disease
-
Indication——
Chemical Information
-
CAS Number207679-81-0
-
Formula Weight341.49
-
Molecular FormulaC22H31NO2
-
Purity98%
-
SolubilityDMSO : ≥ 100 mg/mL; 292.83 mM
-
SMILESCC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(CO)=C1)C(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Nilvebrant L, et al. Pharmacol Toxicol, 1997, 81(4), 169-172.
molnova catalog
related products
-
4SC-202 tosylate
4SC-202 is a selective inhibitor of class I HDAC for HDAC1/2/3 (IC50: 1.20/1.12/0.57 μM). It also displays inhibitory activity against Lysine-specific demethylase 1 (LSD1).
-
Microcystin-LA
Microcystin LA, a natural toxin, exerts its cytotoxic exects by inhibiting the serine-threonine protein phosphatases PP1 and PP2A with IC50s of 0.3 and 0.3 nM, respectively.
-
SHP099
SHP099 free base is an effective, selective, orally bioavailable, and efficacious SHP2 inhibitor (IC50 =0.07 μM and p-ERK modulation in cells IC50 = 0.250 μM). SHP099 shows dose-dependent pathway inhibition and antitumor activity in xenograft models.
